In pursuit of the exceptional responder – Aadi Bioscience, Inc. (ABI), is dedicated to finding the right therapy for the right patient at the right time.
AADi is developing a potentially best-in-class mTOR inhibitor for patients in whom the biology of the disease matches the selectivity of the drug.

For information on our registration study in Advanced Malignant PEComa latest PEC- 001 study, please visit our study page: http://www.mypecomastudy.com/the-pec-001-study/

For information on our Pulmonary Arterial Hypertension study, please visit our study page:
http://pulmonaryhypertension001.com/